Perspective: Is The World Ready For The Next Ebola Outbreak?

HEALTH & WELLNESS

In a part of the Democratic Republic of the Congo, an outbreak that began with a comparatively small number of infections has grown into one of the most serious Ebola emergencies the world has faced.

By 23 September 2026, 7,890 confirmed cases had been reported across 63 health zones in seven provinces of the DRC. Of those infected, 3,799 had died. That represents a crude case-fatality ratio of approximately 48 per cent, a figure that is difficult to comprehend until expressed more simply: almost one in every two confirmed patients has died.

Yet this is not quite the Ebola story much of the world remembers.

The virus driving the outbreak is Bundibugyo virus, one of the viruses capable of causing Ebola disease. It is different from the Ebola virus formerly known as Zaire ebolavirus that caused the devastating West African epidemic of 2014–2016 and has been responsible for several previous outbreaks in the DRC.

That difference has become critically important. The world today possesses an effective licensed vaccine against Ebola disease caused by Ebola virus. It does not yet have an approved vaccine specifically for disease caused by Bundibugyo virus.

The distinction has turned an already dangerous outbreak into a much larger test of global health preparedness. It raises questions extending well beyond the communities presently confronting the disease: Why did this outbreak grow so rapidly? Why, almost two decades after Bundibugyo virus was first identified, is there still no specifically approved vaccine? How much did the world really learn from previous Ebola epidemics and COVID-19? And should people living thousands of kilometres from Central Africa be afraid?

The answer to that last question requires care.

There is every reason for the world to pay attention. There is no reason for the world to panic.

THE EBOLA WE WERE NOT FULLY PREPARED FOR

Ebola is often spoken of as though it were a single virus. It is more complicated than that.

Several viruses belonging to the orthoebolavirus group can cause severe disease in humans. Bundibugyo virus was first identified following an outbreak in western Uganda in 2007. It subsequently caused another recognised outbreak in the Democratic Republic of the Congo in 2012.

The present epidemic, however, is on an entirely different scale.

The World Health Organization has described the 2026 outbreak as spreading with unprecedented speed. What began in Ituri Province expanded across provincial boundaries and eventually reached 63 health zones in seven provinces. By September, it had become the largest Ebola outbreak recorded in the DRC. (who.int)

This scale matters because Ebola containment depends heavily upon speed.

A person becomes infected. Public-health teams must identify the case, isolate and treat the patient, establish whom that person has been in contact with, monitor those contacts, identify further infections quickly and ensure that deaths are handled safely.

When those chains can be reconstructed, outbreaks can be contained.

When health authorities lose sight of transmission chains, the virus gains time.

That is particularly dangerous in places where people regularly move between villages, cities, mining areas and trading centres or cross national borders. Insecurity and population displacement further complicate surveillance. Health workers may struggle to reach communities. Patients may travel long distances before being diagnosed. Families frightened by what an Ebola diagnosis may mean can hesitate to report illness.

An epidemic is therefore never only a contest between medicine and a virus. It is also a contest involving geography, infrastructure, communication, politics and trust.

WHY EBOLA IS SO FEARED

Ebola’s reputation is understandable.

The disease can begin with symptoms that resemble many other illnesses: fever, fatigue, muscle pain, headache and sore throat. Vomiting and diarrhoea may follow, and some patients develop impaired kidney or liver function. Bleeding can occur, although the popular image of Ebola as a disease defined principally by dramatic external bleeding is misleading.

The real danger lies in severe systemic illness and the speed with which patients can deteriorate.

Bundibugyo virus is transmitted primarily through direct contact with blood or other bodily fluids of an infected person, contaminated objects and, in some circumstances, infected animals. People can also become infected through unsafe handling of the body of someone who has died from the disease. (africacdc.org)

That final route has historically made funeral practices an especially sensitive part of Ebola response.

For families, burial is not simply a technical procedure. It is grief, faith, culture and farewell. Public-health teams may need to introduce safe burial practices precisely at the moment when families are experiencing profound loss.

If those measures are imposed without trust or cultural understanding, communities may resist them.

This is one reason successful Ebola response cannot simply arrive wearing protective clothing and carrying medical equipment. It must also listen.

WHEN TRUST BECOMES A MEDICAL TOOL

The importance of community trust is visible in the current outbreak.

WHO surveillance teams working in affected areas have described the painstaking process of locating suspected cases, interviewing families and tracing contacts. They have also encountered hesitation among some families to report sick relatives or cooperate immediately with investigations. (afro.who.int)

Such reluctance should not automatically be dismissed as ignorance.

Communities that have experienced conflict, weak government services, poverty or previous emergencies may have understandable reasons for mistrusting unfamiliar officials. Rumours spread quickly when information is uncertain. Fear of isolation can discourage patients from seeking treatment. Families may worry that relatives taken to treatment centres will never return.

Health workers must therefore achieve something much harder than issuing instructions. They must persuade people that reporting illness is safer than concealing it.

That requires local leaders, community health workers, religious figures and survivors who can speak credibly about treatment and prevention.

It also demonstrates a lesson the world repeatedly learns and forgets: public health cannot function effectively without public trust.

COVID-19 showed the same principle on a global scale. Vaccines, diagnostics and treatments matter enormously, but misinformation, suspicion and poor communication can weaken even sophisticated health systems.

Ebola simply makes the consequences visible much faster.

THE VACCINE PROBLEM

Perhaps the most striking feature of the present outbreak is that the world already has an Ebola vaccine, yet cannot simply deploy it as the complete answer to this epidemic.

The licensed vaccine Ervebo has transformed the response to outbreaks caused by Ebola virus, formerly known as Zaire ebolavirus. WHO has prequalified the vaccine, and it has been used in outbreak-response strategies in which contacts of infected people and contacts of those contacts are vaccinated to create protective rings around cases.

But Bundibugyo virus is different.

There is currently no licensed vaccine specifically approved to prevent Ebola disease caused by Bundibugyo virus. Research is continuing into vaccine candidates and into whether existing approaches might provide useful protection, but the world entered this outbreak without the same proven vaccine tool available for Zaire Ebola. (who.int)

That raises an uncomfortable question.

Bundibugyo virus was first identified in 2007. Why, nearly twenty years later, was there still no approved vaccine specifically ready for it?

There is no simple answer.

Developing vaccines is expensive. Diseases that produce comparatively small and sporadic outbreaks can be extraordinarily difficult to study through conventional clinical trials. Researchers cannot predict exactly when or where the next outbreak will occur, and proving that a vaccine prevents infection requires suitable epidemiological conditions.

Commercial incentives also matter. A vaccine primarily required for occasional outbreaks in poorer countries does not offer pharmaceutical companies the predictable market associated with medicines taken continuously by millions of people.

None of this means that science has ignored Bundibugyo virus. Research has continued, and the present emergency is generating important new evidence.

But the outbreak exposes a persistent weakness in global health: scientific urgency often accelerates dramatically after a threat becomes an emergency.

Preparedness requires investment before the emergency arrives.

UGANDA SHOWS THAT EBOLA CAN BE STOPPED

There is, however, another side to the story, and it deserves attention precisely because Ebola reporting can so easily become dominated by fear.

The virus crossed from the DRC into neighbouring Uganda.

That was exactly the development health authorities feared. Cross-border movement creates opportunities for an outbreak to establish new transmission chains, particularly when communities on either side of a border trade, work and maintain family relationships with one another.

Yet Uganda contained the outbreak.

After the country’s last patient was discharged on 16 July, authorities began the internationally recognised 42-day countdown, twice the maximum incubation period used for declaring an Ebola outbreak over. No further confirmed cases emerged during that period, and Uganda subsequently declared the outbreak ended. (afro.who.int)

That achievement matters.

It demonstrates that cross-border transmission does not inevitably lead to uncontrolled spread. Surveillance, rapid diagnosis, isolation, contact tracing, infection prevention and community cooperation can interrupt transmission.

Imported cases have also been identified farther away, including in France and Germany, without producing sustained transmission outside the DRC. (who.int)

For readers outside the affected region, this is perhaps the most important context.

SHOULD THE REST OF THE WORLD BE AFRAID?

After COVID-19, reports of a rapidly spreading infectious disease understandably produce anxiety.

But Bundibugyo Ebola is not COVID.

The viruses behave differently and spread differently.

Ebola is principally transmitted through direct contact with infected bodily fluids and contaminated materials. It does not spread through everyday community interaction in the manner that respiratory viruses such as influenza or COVID-19 can.

That makes identifying cases and contacts extremely important, but it also makes sustained transmission much more difficult in countries with strong surveillance, infection-control and healthcare systems.

WHO’s latest risk assessment reflects this distinction. The risk within the Democratic Republic of the Congo is assessed as very high. The risk to neighbouring countries is high, particularly because of population movement and cross-border connections. At the broader regional and global level, however, WHO currently assesses the risk as low. (who.int)

That does not mean an infected traveller can never reach another country. The imported cases already demonstrate that possibility.

It means that an imported case and sustained community transmission are very different events.

Someone in India, Britain, Canada, Australia or the Gulf should therefore not interpret the large case numbers in the DRC as evidence that another COVID-style global pandemic is imminent.

Nor should the rest of the world use its relatively low personal risk as an excuse to stop paying attention.

THE WORLD’S ATTENTION PROBLEM

Global health has a recurring weakness.

Diseases command international attention in proportion not only to the suffering they cause but also to the threat wealthy countries believe those diseases pose to themselves.

Ebola illustrates this uncomfortable imbalance particularly well.

When an outbreak remains geographically contained within a poorer African country, international concern can struggle to compete with wars, elections, economic crises and other global events. When an infected traveller arrives in Europe or North America, public attention can change almost overnight.

But viruses do not recognise the political hierarchy of human lives.

An outbreak should matter because people are dying, not merely because there is a possibility that the disease may eventually reach someone richer or farther away.

There is also a practical reason for acting early.

Containing an outbreak near its origin is vastly more effective than waiting until transmission has expanded across regions and borders. Surveillance teams, laboratories, protective equipment, treatment centres and community-health programmes may appear expensive when an outbreak is small. They become remarkably inexpensive compared with the economic and human cost of a large epidemic.

Preparedness is difficult politically because its greatest success is something that never happens.

A laboratory identifies a case before it spreads. A contact tracer finds an infected person before symptoms lead to another chain of transmission. A health worker has the protective equipment that prevents an occupational infection. A community trusts an emergency team enough to report a suspected case.

There is no dramatic photograph of the epidemic that did not occur.

Yet those quiet successes are what global health security is built upon.

WHAT DID WE REALLY LEARN FROM COVID?

COVID-19 was supposed to change the way the world thought about infectious-disease preparedness.

Countries strengthened surveillance. Genomic sequencing expanded. Vaccine technology accelerated dramatically. Governments discovered the importance of supply chains for masks, medicines, diagnostics and oxygen. Public-health agencies gained experience in communicating risk to enormous populations.

But COVID also exposed inequalities that have not disappeared.

Rich countries were able to purchase vaccines and medical supplies more quickly. Poorer countries often waited. Healthcare workers were stretched. Misinformation travelled almost as quickly as infection. Once the immediate emergency faded, political attention and funding began moving elsewhere.

The Bundibugyo outbreak therefore asks a difficult question six years later:

Did the world build a genuinely stronger system, or did it simply become better prepared for the last pandemic?

Future threats will not necessarily resemble COVID-19.

The next major outbreak could be caused by a respiratory virus, a haemorrhagic fever, an antimicrobial-resistant bacterium or a pathogen not yet recognised as a serious human threat.

Preparedness cannot mean maintaining a warehouse labelled “pandemic supplies”.

It means laboratories capable of identifying unusual infections quickly, surveillance systems able to recognise clusters, health workers trained and protected, researchers able to adapt vaccine platforms rapidly, international mechanisms capable of moving money and supplies before an emergency becomes catastrophic, and communities willing to trust the people asking for their cooperation.

AFRICA’S ROLE IS CHANGING

There is another important development that deserves greater recognition.

African countries are not simply waiting for outside institutions to rescue them from infectious diseases.

The Africa Centres for Disease Control and Prevention has become an increasingly important part of continental outbreak surveillance and coordination. African laboratories, epidemiologists, clinicians and community-health workers are leading much of the response to outbreaks occurring on the continent.

The long-term answer to diseases such as Ebola cannot be permanent dependence on emergency teams arriving from elsewhere.

It must include stronger national health systems, regional manufacturing of vaccines and medical products, laboratory capacity, trained personnel and reliable disease surveillance.

The communities most likely to encounter an emerging pathogen first should also possess the resources to identify and contain it first.

That is not charity.

It is global health security.

THE WARNING BEHIND THE NUMBERS

The numbers from the Democratic Republic of the Congo are terrible enough on their own.

Thousands infected. Thousands dead. Seven provinces affected. Families grieving. Health workers confronting a dangerous pathogen. Communities learning once again how quickly ordinary life can be transformed by an outbreak.

But the lesson for the rest of the world is not that Ebola is about to arrive everywhere.

That would be both inaccurate and irresponsible.

The more important warning is that dangerous infectious diseases exploit the spaces where health systems are weakest: delayed diagnosis, poor surveillance, inadequate infrastructure, insecurity, mistrust, insufficient research and the assumption that a disease somewhere else is somebody else’s problem.

Uganda’s successful containment demonstrates what happens when those defences work. The continuing struggle inside the DRC demonstrates what can happen when an outbreak encounters conditions that allow transmission to outrun them.

There will be another emerging infectious-disease emergency. No scientist can say with certainty what pathogen will cause it, where it will begin or when it will happen.

What the world can decide is how prepared it intends to be when that moment comes.

The real warning from the Bundibugyo outbreak is therefore not that everyone should fear Ebola.

It is that the safest time to prepare for the next epidemic is before the world becomes frightened by it.